Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RYGB tops sleeve gastrectomy in long-term outcomes for diabetes

Publish date:: March 8, 2020

Key clinical point: Patients with type 2 diabetes who had Roux-en-Y gastric bypass had better outcomes in weight loss, disease remission and relapse, and glycemic control, compared with those who had sleeve gastrectomy.

Major finding: The estimated cumulative diabetes remission rate 5 years after surgery, was 86% for Roux-en-Y gastric bypass and 84% for sleeve gastrectomy.

Study details: A cohort study with 9,710 adults with type 2 diabetes, who had bariatric surgery between Jan. 1, 2005, and Sept. 30, 2015.

Disclosures: The study was conducted using the National Patient-Centered Clinical Research Network, which was funded by the Patient-Centered Outcomes Research Institute. Dr. McTigue and Dr. Liu had reported no conflicts of interest. Dr. Funk disclosed a Veterans Affairs Health Services Research & Development Career Development Award, and grants from the VA, National Institutes of Health, and American College of Surgeons.

Citation:

McTigue KM et al. JAMA Surg. 2020 Mar 4. doi: 10.1001/jamasurg.2020.0087; Lui N, Funk LM. JAMA Surg. 2020 Mar 4. doi: 10.1001/jamasurg.2020.0088.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan,